No Data
No Data
Earnings Are Growing at Shenzhen Weiguang Biological Products (SZSE:002880) but Shareholders Still Don't Like Its Prospects
Weiguang Biotech: 2024 Semi-Annual Report Summary
Weiguang Biotech: 2024 Semi-Annual Report
Shen Zhen Weiguang Biological Products (002880.SZ) released its half-year performance with a net income of 0.11 billion yuan, a year-on-year growth of 8.75%.
Shen Zhen Weiguang Biological Products (002880.SZ) released its 2024 interim report, with revenue of 0.523 billion yuan, a year-on-year...
Unpleasant Surprises Could Be In Store For Shenzhen Weiguang Biological Products Co., Ltd.'s (SZSE:002880) Shares
Guolian Securities: Supply and demand boost, domestic blood product penetration rate is expected to continue to rise.
The per capita use of blood products in China is less than one-fourth that of developed countries such as the USA, and the demand is showing an increasing trend. As the supply of plasma increases and clinical awareness improves in the future, China's penetration rate is expected to continue to improve.
No Data
No Data